Insulin aspart (AT278) vs insulin glulisine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

Insulin aspart (AT278)

Developed by Arecor Limited

Phase 1 in Type 2 Diabetespeptide
Partial signal

NCT05754424 · Phase 1 · completed

Every participant received AT278 and the active comparator insulin in random order, with neither participants nor staff knowing which was given at each visit, which is a solid design. But the trial measured a pharmacology lab readout rather than a real-world blood sugar or complication outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Area under the glucose infusion rate-time curve of insulin aspart (0 to 60 minutes): Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001). (met)

Result source: NCT05754424

insulin glulisine · Apidra

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT00290927 · Phase 3 · completed

The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.

Reported efficacy

Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. (met)

Result source: NCT00135057

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin aspart (AT278)insulin glulisine
HbA1c, change—Not reported-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
Body weight, change (kg)—Not reported0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result
HbA1c below 7%—Not reported22.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
Fasting plasma glucose, change—Not reported—Not posted · NCT00135057
3-point MACE (% with event)—Not reported—Not posted · NCT00135057

HbA1c, change

Insulin aspart (AT278)
—Not reported
insulin glulisine
-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698

Body weight, change (kg)

Insulin aspart (AT278)
—Not reported
insulin glulisine
0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result

HbA1c below 7%

Insulin aspart (AT278)
—Not reported
insulin glulisine
22.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085

Fasting plasma glucose, change

Insulin aspart (AT278)
—Not reported
insulin glulisine
—Not posted · NCT00135057

3-point MACE (% with event)

Insulin aspart (AT278)
—Not reported
insulin glulisine
—Not posted · NCT00135057
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Insulin aspart (AT278)
Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001). NCT05754424 · Phase 1 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Insulin aspart (AT278): 0 of 4 rows · insulin glulisine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin glulisine
Dropout rate
23.5%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
20%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.6%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
2.6%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
Serious AEs
11.9%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
11.3%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
2%
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
6.5%Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
0%Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
any infections and infestations 42.3%
any musculoskeletal and connective tissue disorders 22.7%
any gastrointestinal disorders 16.5%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
any infections and infestations 34%
any musculoskeletal and connective tissue disorders 23.2%
any nervous system disorders 20.1%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
uterine leiomyoma 6.7%
arthralgia 6.5%
headache 6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 11.9%
diarrhoea 8.5%
nasopharyngitis 5.1%
NCT01194258 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin glulisine

HbA1c Less Than 7% 43.3% (n=187) vs 38.6% (n=189) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
44.1% (n=195) vs 38.1% (n=197) Novolog Mix 70/30 @ 60wk
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c -2.3% (n=138) vs -1.97% (n=134) Novolog Mix 70/30 @ 60wk
absolute change · percentage points
Absolute change in HbA1c from baseline
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c -2.45% (n=144) vs -2.13% (n=134) Novolog Mix 70/30 @ 60wk
absolute change · percentage points
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
-0.37% (n=49) vs -0.11% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wk
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
-0.48% (n=115) vs -0.46% (n=115) Insulin Lispro
NCT01194258 · Phase 2 · registry result, not featured evidence
HbA1c Less Than 7% 51.1% (n=180) vs 39.5% (n=185) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
22.4% (n=49) vs 8.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wk
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Severe or BG Confirmed Hypoglycemia 23% (n=183) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
25% (n=180) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c 7.5% (n=49) vs 7.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wk
absolute value · percentage points
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
Daily Plasma Glucose Change mg/dL -0.83 vs -0.11 Insulin Glargine+Metformin+Glimepiride mmol/L @ 24wk
absolute change · mmol/L
NCT00360698 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -15.01 mg/dL as posted
Weight 0.46 vs 0.22 Insulin Glargine+Metformin+Glimepiride kg @ 24wk
absolute change · kg
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
1.5 vs 1.6 Insulin-lispro kg*
NCT01194258 · Phase 2 · registry result, not featured evidence · converted to kg from 3.35 pounds as posted
Symptomatic Hypoglycemia 8.19% (n=49) vs 7.68% (n=57) Insulin Glargine+Metformin+Glimepiride
event rate · % of participants
NCT00360698 · Phase 4 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (AT278)'s landscape · insulin glulisine's landscape